|
Trellus Health PLC on Friday said it signed a contract with ‘one of the largest global clinical research organisations’. The London-based healthcare company said the 12-month contract is to utilise its Trellus TrialSet offering. The contract is set to start before the end of 2025, and will focus on immunology and inflammation supporting recruitment and enrolment optimisation for two late-stage clinical trials. Trellus Health added that the contract comes with an upfront fee, a monthly management fee and milestone payments. Chief Executive Officer Marla Dubinsky said: ‘This represents another important milestone for Trellus Health, underscoring the intrinsic value of our Trellus TrialSet digital solution and reflecting our continued focus on strategic execution. Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering. While the contract does not immediately extend the company’s current cash runway beyond early December 2025, combined with the patient support program agreement signed with Johnson & Johnson in January 2025 which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector.’ She added that Trellus Health continues to explore options for potential equity financing, with further updates to be provided in due course. Trellus Health shares fell 9.2% to 0.50 pence each on Friday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
